Camp4 Therapeutics Poration Stock Performance
| CAMP Stock | USD 4.46 0.95 17.56% |
The firm shows a Beta (market volatility) of -0.76, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning CAMP4 THERAPEUTICS are expected to decrease at a much lower rate. During the bear market, CAMP4 THERAPEUTICS is likely to outperform the market. At this point, CAMP4 THERAPEUTICS has a negative expected return of -1.75%. Please make sure to confirm CAMP4 THERAPEUTICS's value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if CAMP4 THERAPEUTICS performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CAMP4 THERAPEUTICS PORATION has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (11.27) | Five Day Return (26.60) | Year To Date Return (19.46) | Ten Year Return (98.85) | All Time Return (96.02) |
1 | Disposition of 487 shares by Jikun Kim of CalAmp Corp at 3.68 subject to Rule 16b-3 | 05/03/2024 |
2 | Global Commercial Vehicle Telematics Industry Research 2024 Market to Reach 37.6 Billion by 2030, Innovation in Telematics Services to Boost Revenue Potential -... | 05/24/2024 |
3 | Disposition of 15 shares by Nathan Lowstuter of CalAmp Corp at 0.8766 subject to Rule 16b-3 | 06/12/2024 |
4 | CAMP4 Therapeutics prices 75MIPO at 11 per share | 10/11/2024 |
5 | Camp4 Therapeutics sees 9.99 million stock purchase by Polaris | 10/15/2024 |
6 | Insider Trading Activity Tuesday Top Buys and Sells in US Stocks Revealed | 10/16/2024 |
7 | Camp4 Therapeutics sees 8.4 million stock purchase by Northpond Ventures | 10/17/2024 |
8 | Disposition of 1448 shares by Clark Jeffrey P. of CAMP4 THERAPEUTICS subject to Rule 16b-3 | 10/18/2024 |
9 | UNDER CANVAS ANNOUNCES FIRST PACIFIC NORTHWEST CAMP IN THE COLUMBIA RIVER GORGE REGION OF WASHINGTON, NEAR OREGONS MOUNT HOOD | 10/22/2024 |
10 | Erykah Badu, Playboi Carti, MF Doom tribute, Sexyy Red and more bring the heat to Camp Flog Gnaw on Day 2 | 11/18/2024 |
| Begin Period Cash Flow | 84.5 M |
CAMP4 |
CAMP4 THERAPEUTICS Relative Risk vs. Return Landscape
If you would invest 1,072 in CAMP4 THERAPEUTICS PORATION on August 27, 2024 and sell it today you would lose (531.00) from holding CAMP4 THERAPEUTICS PORATION or give up 49.53% of portfolio value over 90 days. CAMP4 THERAPEUTICS PORATION is currently does not generate positive expected returns and assumes 8.5274% risk (volatility on return distribution) over the 90 days horizon. In different words, 75% of stocks are less volatile than CAMP4, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CAMP4 THERAPEUTICS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CAMP4 THERAPEUTICS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CAMP4 THERAPEUTICS PORATION, and traders can use it to determine the average amount a CAMP4 THERAPEUTICS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2051
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CAMP |
Estimated Market Risk
| 8.53 actual daily | 75 75% of assets are less volatile |
Expected Return
| -1.75 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CAMP4 THERAPEUTICS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CAMP4 THERAPEUTICS by adding CAMP4 THERAPEUTICS to a well-diversified portfolio.
CAMP4 THERAPEUTICS Fundamentals Growth
CAMP4 Stock prices reflect investors' perceptions of the future prospects and financial health of CAMP4 THERAPEUTICS, and CAMP4 THERAPEUTICS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CAMP4 Stock performance.
| Price To Earning | 318.57 X | ||||
| Revenue | 186.23 M | ||||
| EBITDA | (8.72 M) | ||||
| Net Income | (49.29 M) | ||||
| Cash And Equivalents | 47.72 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 178.68 M | ||||
| Current Ratio | 1.86 X | ||||
| Book Value Per Share | (45.01) X | ||||
| Cash Flow From Operations | (44.16 M) | ||||
| Earnings Per Share | (63.02) X | ||||
| Market Capitalization | 660.34 K | ||||
| Total Asset | 54.95 M | ||||
| Retained Earnings | (159.96 M) | ||||
| Working Capital | 32.21 M | ||||
| Current Asset | 298.77 M | ||||
| Current Liabilities | 49.56 M | ||||
About CAMP4 THERAPEUTICS Performance
Assessing CAMP4 THERAPEUTICS's fundamental ratios provides investors with valuable insights into CAMP4 THERAPEUTICS's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the CAMP4 THERAPEUTICS is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.22) | |
| Days Of Inventory On Hand | 60.25 | 68.30 | |
| Return On Capital Employed | (0.04) | (0.05) | |
| Return On Assets | (0.16) | (0.15) | |
| Return On Equity | (0.57) | (0.54) |
Things to note about CAMP4 THERAPEUTICS performance evaluation
Checking the ongoing alerts about CAMP4 THERAPEUTICS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CAMP4 THERAPEUTICS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CAMP4 THERAPEUTICS generated a negative expected return over the last 90 days | |
| CAMP4 THERAPEUTICS has high historical volatility and very poor performance | |
| CAMP4 THERAPEUTICS has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 186.23 M. Net Loss for the year was (49.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CAMP4 THERAPEUTICS PORATION currently holds about 47.72 M in cash with (44.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| CAMP4 THERAPEUTICS has a frail financial position based on the latest SEC disclosures | |
| Latest headline from aol.com: Erykah Badu, Playboi Carti, MF Doom tribute, Sexyy Red and more bring the heat to Camp Flog Gnaw on Day 2 |
- Analyzing CAMP4 THERAPEUTICS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CAMP4 THERAPEUTICS's stock is overvalued or undervalued compared to its peers.
- Examining CAMP4 THERAPEUTICS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CAMP4 THERAPEUTICS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CAMP4 THERAPEUTICS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CAMP4 THERAPEUTICS's stock. These opinions can provide insight into CAMP4 THERAPEUTICS's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CAMP4 Stock Analysis
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.